Phase II was planned to be completed June 2007, according to http://clinicaltrials.gov/ct/show/NCT00382629
For anyone interested in some details:
BHT-3009 is a plasmid (dna molecule) coding for the cDNA of MBP (myelin basic protein). In addition, the dna sequence of the plasmid backbone was "optimized" replacing the immunostimulating CpGs (> DNA = A, T, G, C) by immunoinhibitory GpGs (published http://www.jimmunol.org/cgi/content/ful ... 09c712e358
). That should give a synergistic effect...
Here the study results http://archneur.ama-assn.org/cgi/conten ... v1?papetoc
The MRI data is not so impressive (maybe also because of the small number of persons in the study), but I found the FACS (flow cytometer, to sort cells) data quite convincing: It showed a dramatic decrease of MBP-specific T-cell response for weeks.